A detailed history of Royal Bank Of Canada transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Royal Bank Of Canada holds 30,322 shares of IMCR stock, worth $917,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,322
Previous 44,970 32.57%
Holding current value
$917,240
Previous $1.4 Million 36.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$28.14 - $34.69 $412,194 - $508,139
-14,648 Reduced 32.57%
30,322 $894,000
Q3 2024

Nov 14, 2024

BUY
$30.06 - $41.49 $15,480 - $21,367
515 Added 1.16%
44,970 $1.4 Million
Q2 2024

Aug 14, 2024

BUY
$33.78 - $63.75 $72,897 - $137,572
2,158 Added 5.1%
44,455 $1.51 Million
Q1 2024

Nov 05, 2024

SELL
$60.14 - $75.36 $129,782 - $162,626
-2,158 Reduced 4.85%
42,297 $2.75 Million
Q1 2024

May 15, 2024

BUY
$60.14 - $75.36 $4,390 - $5,501
73 Added 0.17%
42,297 $2.75 Million
Q4 2023

Feb 14, 2024

BUY
$42.85 - $69.5 $384,235 - $623,206
8,967 Added 26.96%
42,224 $2.88 Million
Q3 2023

Nov 14, 2023

BUY
$49.5 - $66.6 $471,289 - $634,098
9,521 Added 40.11%
33,257 $1.73 Million
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $1.15 Million - $1.46 Million
23,705 Added 76467.74%
23,736 $1.42 Million
Q1 2023

May 15, 2023

BUY
$46.12 - $65.71 $1,014 - $1,445
22 Added 244.44%
31 $1,000
Q4 2022

Feb 14, 2023

SELL
$45.51 - $65.08 $11,331 - $16,204
-249 Reduced 96.51%
9 $0
Q3 2022

Nov 14, 2022

SELL
$37.34 - $57.44 $89,616 - $137,856
-2,400 Reduced 90.29%
258 $12,000
Q1 2022

May 16, 2022

BUY
$18.94 - $34.29 $50,342 - $91,142
2,658 New
2,658 $79,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.33B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.